Arthritis : Timely Treatments for an Ageless Disease
by Carol Lewis
MYTH: Arthritis affects only older people.
FACT: Arthritis affects any age, including children.
There's no question that the incidence of arthritis increases with age,
but nearly three of every five sufferers are under age 65.
MYTH: Arthritis is just minor aches and pains.
FACT: Arthritis can be permanently debilitating.
MYTH: Arthritis cannot be treated.
FACT: FDA recently approved several new treatments
for osteoarthritis and rheumatoid arthritis.
The fact is, these myths keep people from seeking a
doctor's help against the number one cause of disability in the United States,
according to the national Centers for Disease Control and Prevention. Arthritis
disables more Americans than heart disease and stroke, and CDC says it's
what Americans don't know about the disease that can hurt them.
"People ignore arthritis both as public and personal
health problems because it doesn't kill you," says Chad Helmick, a
medical epidemiologist at CDC. "But what they don't realize is that
as Americans work and live longer, arthritis can affect their quality of
life and eventually lead to disability." Current costs to the U.S.
economy total nearly $65 billion annually--an impact equal to a moderate
recession.
And the extent of the suffering is going to get worse.
Arthritis already affects more than 42 million Americans in its chronic
form, including 300,000 children. By 2020, CDC estimates that 60 million
people will be affected, and that more than 11 million will be disabled.
The Arthritis Foundation and the American College of
Rheumatology agree that awareness, early diagnosis, and an aggressive treatment
plan developed by a doctor are key to stopping arthritis from taking over
your life.
What Is Arthritis?
Although the term literally means joint inflammation,
arthritis really refers to a group of more than 100 rheumatic diseases and
conditions that can cause pain, stiffness and swelling in the joints. Certain
conditions may affect other parts of the body--such as the muscles, bones,
and some internal organs--and can result in debilitating, and sometimes
life-threatening, complications. If left undiagnosed and untreated, arthritis
can cause irreversible damage to the joints.
The two most common forms of the disease, osteoarthritis
and rheumatoid arthritis, have the greatest public health implications,
according to the Arthritis Foundation.
Osteoarthritis, previously known as "degenerative
joint disease," results from the wear and tear of life. The pressure
of gravity--the load of living--causes physical damage to the joints and
surrounding tissues, leading to pain, tenderness, swelling, and decreased
function. Initially, osteoarthritis is noninflammatory and its onset is
subtle and gradual, usually involving one or only a few joints. The joints
most often affected are the knee, hip and hand. Pain is the earliest symptom,
usually made worse by repetitive use. Osteoarthritis affects more than 20
million people, and the risk of getting it increases with age. Other risk
factors include joint trauma, obesity, and repetitive joint use.
Rheumatoid arthritis is an autoimmune disease
that occurs when the body's own immune system mistakenly attacks the synovium
(cell lining inside the joint). This chronic, potentially disabling disease
causes pain, stiffness, swelling, and loss of function in the joints.
To see an illustration of the cross section of a normal
knee joint and the effects of osteoarthritis and rheumatoid arthritis, select
the graphic at right.
While the cause remains elusive, doctors suspect that
genetic factors are important in rheumatoid arthritis. Recent studies have
begun to tease out the genetic characteristics that can be passed from generation
to generation. However, the inherited trait alone does not cause the illness.
Researchers think this trait, along with some other unknown factor--probably
in the environment--triggers the disease.
But rheumatoid arthritis can be difficult to diagnose
early because it may begin gradually with subtle symptoms. According to
CDC, this form of arthritis affects more than 2 million people in the United
States, and two to three times more women are affected than men.
Finding Effective Treatments
For years, the pain and inflammation of arthritis have
been treated with varying success, using medications, local steroid injections,
and joint replacement. Seldom did the therapies make the pain go away completely
or for very long, nor did they affect the underlying joint damage. Just
ask Jo Ellen Gluscevich, who has tried more drugs and treatments than she
can remember, to no avail.
"It seems I've tried them all," says the 50-year-old
from Frederick, Md., who was diagnosed with rheumatoid arthritis 10 years
ago. "Every year continues to be a challenge for me medically."
But now there are some new treatments available, and
patients should consult with their doctors to determine which are the most
appropriate for their conditions.
Osteoarthritis
When taken regularly and at high doses, traditional
nonsteroidal anti-inflammatory drugs (NSAIDs) used for pain relief can cause
gastrointestinal (GI) bleeding or ulcers. But a new type of NSAID, cyclooxygenase-2
inhibitors, better known as COX-2 inhibitors, has joined the old
standbys and helps suppress arthritis with less stomach irritation.
Cyclooxygenases are enzymes needed for the synthesis
of hormone-like substances called prostaglandins. There are two types of
cyclooxygenases: the COX-2 enzyme that mediates inflammation and pain, and
the COX-1 enzyme that helps maintain other physiological functions in the
body. Traditional NSAIDs inhibit both enzymes. The new NSAIDs, however,
block mostly the COX-2 enzyme, offering a new treatment option for people
who have had difficulty tolerating the old NSAIDs.
"COX-2 inhibitors are just as effective in treating
osteoarthritis as other NSAIDs," says Maria Villalba, M.D., a medical
officer with FDA's Center for Drug Evaluation and Research. "And they
have similar renal effects, liver effects and the potential for allergic
reactions. But they seem to have a better GI safety profile than traditional
NSAIDs."
FDA approved the first COX-2 inhibitor, Celebrex
(celecoxib), in December 1998 to treat rheumatoid arthritis and
osteoarthritis. Vioxx (refecoxib) became the second COX-2
inhibitor to receive approval, in May 1999, but only for the treatment of
osteoarthritis, dysmenorrhea (pain with menstrual periods), and the relief
of acute pain in adults, such as that caused by dental surgery.
Both drugs, taken orally, were found to substantially
lower the risk of stomach and upper intestinal ulcers detected by endoscopy
in clinical trials, compared with other NSAIDs. Additional studies are needed
to determine whether Celebrex and Vioxx actually cause fewer serious stomach
problems, including GI ulceration, bleeding and perforation. Until such
studies are done, FDA is requiring the drugs' labeling to include the standard
warning about the GI risks that are associated with NSAIDs.
Two non-drug alternatives for the treatment of pain
in osteoarthritis of the knee were approved by the Center for Devices and
Radiological Health in 1997 for patients who have failed to respond adequately
to simple analgesics, such as acetaminophen, and to conservative nonpharmacologic
therapy. Hyalgan and Synvisc are viscous solutions
composed of hyaluronan (hyaluronic acid, a lubricant found naturally in
the joints), and are injected directly into the knee joint. Both are believed
to increase the quality of synovial fluid, although the mechanism of action
for these products is not well understood. The most common side effects
reported from these treatments--injection site pain and knee pain and/or
swelling--were found to be temporary. For patients who cannot tolerate oral
medications and who are not candidates for surgical knee replacement, these
treatments may be an ideal option.
Rheumatoid Arthritis
In recent years, the typical treatments for rheumatoid
arthritis relied on combination NSAIDs, such as ibuprofen and aspirin. These
drugs reduce swelling and alleviate pain but do little to change the course
of the disease. Another class of treatments relied on disease-modifying,
antirheumatic drugs (DMARDs), such as methotrexate and sulfasalazine. DMARDs
work to slow inflammation and can, in many cases, alter the course of the
disease. Because of their adverse effects, most doctors reserved these more
powerful drugs for patients who failed to respond to other therapies. Now,
many physicians are using DMARDs early and aggressively in the hope of slowing
disease progression and preventing damage to joints and internal organs.
The most recently approved treatment regimen for rheumatoid
arthritis is one that combines the genetically engineered biological drug
Remicade (infliximab) with the drug methotrexate. (Not all
patients with rheumatoid arthritis can tolerate or respond to methotrexate
alone, a standard treatment for the disease.) Remicade is the second in
a new class of drugs known as biologic response modifiers, which bind to
and block the action of a naturally occurring protein called tumor necrosis
factor (TNF), believed to play a role in joint inflammation and damage.
Elevated levels of TNF are found in the synovial fluid of rheumatoid arthritis
patients.
Remicade, which is administered intravenously by a health-care
professional in a two-hour outpatient procedure, was approved by FDA in
November 1999 to reduce the signs and symptoms in patients who have not
experienced significant relief from methotrexate alone.
Approved in November 1998, Enbrel (etanercept)
is the first biologic response modifier to receive FDA approval for
patients with moderate to severe rheumatoid arthritis. Taken twice weekly
by injection, Enbrel was shown to decrease pain and morning stiffness and
improve joint swelling and tenderness. In June 2000, the drug's uses were
expanded to include delaying structural damage.
Jeffrey N. Siegel, M.D., a medical officer with FDA's
Center for Biologics Evaluation and Research, says that Enbrel is an exciting
breakthrough because it helps a majority of patients who have not responded
to any of the other commonly used therapies. Although it is injected, the
treatment can be administered at home. In addition, Enbrel has been shown
to be effective for children with the juvenile form of rheumatoid arthritis.
In clinical trials, Enbrel was generally well tolerated, and one of the
most common side effects was an injection site reaction.
Both Remicade and Enbrel show promise in treating rheumatoid
arthritis, although the long-term risks and benefits of these drugs are
unknown.
Arava (leflunomide) is the first oral
treatment approved for slowing the progression of rheumatoid arthritis.
Although its effects are similar to those of methotrexate, this drug works
by a different chemical mechanism, blocking an enzyme in certain lymphocytes
(a type of white blood cell that is part of the immune system) and thereby
retarding the progression of the disease.
Arava is not a cure, however, and studies have suggested
that the drug may cause birth defects. Therefore, its labeling carries a
special warning for pregnant women, women of childbearing age, and those
who want to become pregnant.
The first non-drug alternative for adult patients with
moderate to severe rheumatoid arthritis and longstanding disease who have
failed or cannot tolerate DMARDs was approved by FDA in March 1999. The
Prosorba column, which was initially approved in 1987 to treat
an immune blood disorder, is a single-use medical device, about the size
of a coffee mug, containing a material that binds antibodies and antigen-antibody
complexes.
In a two-hour process performed in a hospital or specialized
treatment center, a patient's blood is removed and passed through a machine
that separates the blood cells from the plasma (the liquid portion of the
blood). The plasma is then passed through the Prosorba column, recombined
with the blood cells, and returned to the patient. Although this filtering
process is believed to remove proteins that may inadvertently attack the
joint cells, the mechanism of action of the Prosorba column is not well
understood. The treatment is given once a week for 12 weeks. The most common
side effects include joint pain and/or swelling, fatigue, hypotension (low
blood pressure), and anemia.
"For those patients who have failed or are intolerant
to DMARDs, including Arava and the anti-TNF agents," says Sahar M.
Dawisha, M.D., a medical officer in FDA's Center for Devices and Radiological
Health, "the Prosorba column may be an additional treatment option."
Exercise and Arthritis
Proper exercises performed on a regular basis are an
important part of arthritis treatment, according to the Arthritis Foundation.
Twenty years ago, doctors advised exactly the opposite, fearing that activity
would cause more damage and inflammation. Not exercising causes weak muscles,
stiff joints, reduced mobility, and lost vitality, say rheumatologists,
who now routinely advise a balance of physical activity and rest.
According to the 1996 Surgeon General's Report on
Physical Activity and Health, regular, moderate physical activity is
beneficial in decreasing fatigue, strengthening muscles and bones, increasing
flexibility and stamina, and improving the general sense of well-being.
The National Institutes of Health advises that the amount and form of exercise
should depend on which joints are involved, the amount of inflammation,
how stable the joints are, and whether a joint replacement procedure has
been done. A skilled physician who is knowledgeable about the medical and
rehabilitation needs of people with arthritis, working with a physical therapist,
can design an exercise plan for each patient.
Three main types of exercises are recommended:
- Range-of-motion--moving a joint as far as
it will comfortably go and then stretching it a little further to increase
and maintain joint mobility, decrease pain, and improve joint function.
These can be done daily, or at least every other day.
- Strengthening--using muscles without moving
joints to help increase muscle strength and stabilize weak joints. These
can be done daily, or at least every other day, unless there is severe
pain or swelling.
- Endurance--aerobic exercises such as walking,
swimming and bicycling to strengthen the heart and lungs and increase
stamina. These should be done for 20 to 30 minutes, three times a week,
unless there is severe pain or swelling.
Unproven Remedies
Many people with arthritis become discouraged with typical
treatments because the disease progresses over time and the symptoms worsen.
Consequently, they search for alternative therapies aimed at arthritis.
But arthritis patients need to be careful because treatments not shown to
be safe and effective through controlled scientific studies may be dangerous.
According to the Arthritis Foundation, the benefits of a treatment in controlling
arthritis should be greater than the risk of unwanted or harmful effects.
Since arthritis symptoms may come and go, a person using an unproven remedy
may mistakenly think the remedy worked simply because he or she tried it
when symptoms were going into a natural remission.
Two controversial nutritional supplements, not approved
by FDA, have catapulted into the spotlight because of claims that they rebuild
joint tissues damaged by osteoarthritis--or halt the disease entirely. But
at this time, the use of glucosamine and chondroitin
sulfate supplements warrant further in-depth studies on their safety
and effectiveness, according to the Arthritis Foundation. NIH plans to study
the effectiveness of these supplements.
Both glucosamine and chondroitin sulfate occur in the
body naturally and are vital to normal cartilage formation, but the Arthritis
Foundation says there's no evidence that swallowed chondroitin is absorbed
into the body and deposited into the joints. Moreover, no one knows how
much glucosamine and chondroitin sulfate are in the bottles since current
law does not require dietary supplements to be manufactured under the same
good manufacturing practice standards as pharmaceuticals. As reported in
the December 1999 UC Berkeley Wellness Letter, "It's a hit-or-miss
proposition because there's no standardization and no guarantee that you're
getting what the label says."
The Arthritis Foundation urges anyone considering using
these supplements to become "fully educated about potential positive
and negative effects." In addition, people are encouraged to consult
their physicians about how the supplements fit within their existing treatment
regimens. Above all, do not stop proven treatments and disease-management
techniques in favor of the supplements.
The Arthritis Foundation also says that copper bracelets,
mineral springs, vibrators, magnets, vinegar and honey, dimethyl sulfoxide,
large doses of vitamins, drugs with hidden ingredients (such as steroids),
and snake venom are all unproven remedies. And any unproven remedy, no matter
how harmless, can become harmful if it stops or delays someone from seeking
a prescribed treatment program from a knowledgeable physician.
Prevention Measures
There are ways to help prevent arthritis. Both CDC and
the American College of Rheumatology recommend maintaining ideal weight,
taking precautions to reduce repetitive joint use and injury on the job,
avoiding sports injuries by performing warm-ups and strengthening exercises
using weights, and by choosing appropriate sports equipment.
Lyme arthritis may develop after a bacterial infection
is transmitted to humans through tick bites. To prevent this type of arthritis,
health experts advise people to use insect repellents, wear long-sleeved
shirts and pants while walking near wooded areas, and check for and remove
ticks to help reduce the risk of getting the disease. CDC also recommends
the prompt use of antibiotics for Lyme disease symptoms. In December 1998,
FDA approved the first vaccine, Lymerix, to help prevent Lyme disease.
Hope for the Future
The recent rise in the number of effective new arthritis
treatments offers the hope that still better therapies are just over the
horizon. For Jo Ellen Gluscevich, the results have not been so dramatic.
She remains mostly housebound and must avoid crowds because her immune system
is compromised and susceptible to infection. But as the population ages
and arthritis becomes a growing problem, the Arthritis Foundation believes
that "more physicians are recognizing the severity of the disease and
the need for a broader approach toward treatment."
Other Forms of Arthritis and Related Conditions
In addition to rheumatoid and osteoarthritis, there
are a number of diseases and conditions that can cause joint pain and stiffness.
Juvenile arthritis is a general term for
all types of arthritis that occur in children. Juvenile rheumatoid arthritis
is the most prevalent form in children, and there are three major types:
polyarticular (affecting many joints), pauciarticular (pertaining to only
a few joints), and systemic (affecting the entire body). The signs and symptoms
of juvenile rheumatoid arthritis vary from child to child. There is no single
test that establishes conclusively a diagnosis of juvenile arthritis, and
the condition must be present consistently for six or more consecutive weeks
before a correct diagnosis can be made. Heredity is thought to play some
part in the development of juvenile arthritis. However, the inherited trait
alone does not cause the illness. Researchers think this trait, along with
some other unknown factor (probably in the environment), triggers the disease.
The Arthritis Foundation says that juvenile arthritis is even more prevalent
than juvenile diabetes and cerebral palsy.
Gout is a disease that causes sudden,
severe attacks of pain, tenderness, redness, warmth, and swelling in some
joints. It usually affects one joint at a time, especially the joint of
the big toe. The pain and swelling associated with gout are caused by uric
acid crystals that precipitate out of the blood and are deposited in the
joint. Factors leading to increased levels of uric acid and then gout include
excessive alcohol intake, hypertension, kidney disease, and certain drugs.
Ankylosing spondylitis is a chronic inflammatory
disease of the spine that can fuse the vertebrae to produce a rigid spine.
Spondylitis is a result of inflammation that usually starts in tissue outside
the joint. The most common early symptoms of spondylitis are low back pain
and stiffness that continues for months. Although the cause of spondylitis
is unknown, scientists have discovered a strong genetic or family link,
according to the Arthritis Foundation. Most people with spondylitis have
a genetic marker known as HLA-B27. Genetic markers are protein molecules
located on the surface of white blood cells that act as a type of "name
tag." Having this genetic marker does not mean a person will develop
spondylitis, but people with the marker are more likely to develop the disease
than those without. Ankylosing spondylitis usually affects men between the
ages of 16 and 35, but it also affects women. Other joints besides the spine
may be involved.
Systemic lupus erythematosus is an autoimmune
disease that can involve the skin, kidneys, blood vessels, joints, nervous
system, heart, and other internal organs. Symptoms vary among those affected,
but may include a skin rash, arthritis, fever, anemia, hair loss, ulcers
in the mouth, and kidney sediment or function abnormalities. In most cases,
the symptoms first appear in women of childbearing age; however, lupus can
occur in young children or older people. Studies suggest that there is an
inherited tendency to get lupus. Lupus affects women about 9 to 10 times
as often as men. It is also more common in African-American women.
Related Arthritis Conditions
Bursitis, tendinitis and myofascial pain
are localized, nonsystemic (not affecting the whole body) painful conditions.
Bursitis is inflammation of the sac surrounding any joint that contains
a lubricating fluid. Tendinitis is inflammation of a tendon, and myofascial
pain is a problem that results from the strain or improper use of a muscle.
These conditions may start suddenly, and usually stop within a matter of
days or weeks.
Carpal tunnel syndrome is a condition
in which pressure on the median nerve at the wrist causes tingling and numbness
in the fingers. It can begin suddenly or gradually, and can be associated
with another disease, such as rheumatoid arthritis, or it may be unrelated
to other conditions. If untreated, it can result in permanent nerve and
muscle damage. With early diagnosis and treatment, there is an excellent
chance of complete recovery.
Fibromyalgia syndrome is a condition with
generalized muscular pain, fatigue, and poor sleep that is believed to affect
approximately 2 percent of the U.S. population, or 5 million people. The
name fibromyalgia means pain in the muscles, ligaments and tendons. The
condition mainly affects muscles and their attachments to bones. Although
it may feel like a joint disease, the Arthritis Foundation says it is not
a true form of arthritis and does not cause deformities of the joints. Fibromyalgia
is instead a form of soft tissue or muscular rheumatism.
Infectious arthritis is a form of joint
inflammation that is caused by bacteria, viruses or fungi. The diagnosis
is made by culturing the organism from the joint. Most infectious arthritis
can be cured by antibiotic medications.
Psoriatic arthritis is similar to rheumatoid
arthritis. About 5 percent of people with psoriasis, a chronic skin disease,
also develop psoriatic arthritis. In psoriatic arthritis, there is inflammation
of the joints and sometimes the spine. Fewer joints may be involved than
in rheumatoid arthritis, and there is no rheumatoid factor in the blood.
Reiter's syndrome involves inflammation
in the joints, and sometimes where ligaments and tendons attach to bones.
This form of arthritis usually develops following an intestinal or a genital/urinary
tract infection. People with Reiter's syndrome have arthritis and one or
more of the following conditions: urethritis, prostatitis, cervicitis, cystitis,
eye problems, or skin sores.
Scleroderma is a disease of the body's
connective tissue that causes thickening and hardening of the skin. It can
also affect joints, blood vessels, and internal organs. There are two types
of scleroderma: localized and generalized.
Carol Lewis is a staff writer for FDA Consumer. This
article originally appeared in the FDA Consumer magazine, published
by the U.S. Food and Drug Administration, in the May-June 2000 issue.
Related Videos
|
|